Design, Production and Characterization of Peptide Antibodies—Volume II

A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Antibody Discovery and Engineering".

Deadline for manuscript submissions: closed (31 August 2024) | Viewed by 4926

Special Issue Editors


E-Mail Website
Guest Editor
Department of Neurology, Rigshospitalet Glostrup, Valdemar Hansens vej 1-23, 2600 Glostrup, Denmark
Interests: rheumatoid arthritis; anti-citrullinated protein antibodies; citrullinated epitopes; cyclic citrullinated peptides
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
Department of Neurology, Rigshospitalet Glostrup, Nordre Ringvej 57, 2600 Glostrup, Denmark
Interests: antibodies; aptamers; peptides; peptide antibodies; recognition molecules; synthetic libraries
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Antibodies are key reagents in diagnostics and experimental biology, capable of detecting numerous antigenic targets. Proteins are often in focus and are usually effective targets for antibody production. Occasionally, however, the native protein is known but not available, or a very specific target is required. In these cases, synthetic peptides, copying essential sequences from the target, are good alternatives for antibody production. Peptide antibodies have been used in diagnostics and experimental biology with great success, especially because they can be produced to multiple targets, for example, native and denatured targets: In particular, mutation-specific antibodies have become important as diagnostic tools in malignant and premalignant conditions. Thus, peptide antibodies have become powerful tools and are readily produced to any peptide of choice, if appropriate precautions are taken.

When selecting or designing the peptide used for antibody production, critical elements (among others) include peptide length, structure, and amino acid composition, but elements such as peptide synthesis limitations and peptide antibody accessibility to the intended target are also critical for a good outcome.

Traditional peptide antibody proteins encompass animal-based immunization with a synthetic peptide, usually conjugated to a carrier protein to enhance immune presentation, as small peptides tend not to be immunogenic by themselves. There are several strategies for the conjugation of peptides to carriers applied for immunization. This is the most used approach for peptide antibody production. In addition to traditional peptide antibody production, peptide antibodies can be produced using libraries or sequencing.

Following peptide antibody production, newly generated peptide antibodies are typically characterized based on their reactivity in immunoassays (e.g., enzyme-linked immunosorbent assays or surface plasmon resonance), where antibody specificity and reactivity are determined.   

This Special Issue “Design, Production and Characterization of Peptide Antibodies” aims to describe the current state-of-the-art techniques and characterization/applications within the field as well as newer and emerging uses of peptide antibodies.

Dr. Nicole H. Trier
Prof. Dr. Gunnar Houen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibodies
  • antibody production
  • peptide antibodies
  • diagnostics
  • mutation-specific antibodies
  • critical elements, including peptide length
  • structure and amino acid composition

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1995 KiB  
Article
Cost-Effective Protein Production in CHO Cells Following Polyethylenimine-Mediated Gene Delivery Showcased by the Production and Crystallization of Antibody Fabs
by Klaudia Meskova, Katarina Martonova, Patricia Hrasnova, Kristina Sinska, Michaela Skrabanova, Lubica Fialova, Stefana Njemoga, Ondrej Cehlar, Olga Parmar, Petr Kolenko, Vladimir Pevala and Rostislav Skrabana
Antibodies 2023, 12(3), 51; https://doi.org/10.3390/antib12030051 - 4 Aug 2023
Viewed by 4429
Abstract
Laboratory production of recombinant mammalian proteins, particularly antibodies, requires an expression pipeline assuring sufficient yield and correct folding with appropriate posttranslational modifications. Transient gene expression (TGE) in the suspension-adapted Chinese Hamster Ovary (CHO) cell lines has become the method of choice for this [...] Read more.
Laboratory production of recombinant mammalian proteins, particularly antibodies, requires an expression pipeline assuring sufficient yield and correct folding with appropriate posttranslational modifications. Transient gene expression (TGE) in the suspension-adapted Chinese Hamster Ovary (CHO) cell lines has become the method of choice for this task. The antibodies can be secreted into the media, which facilitates subsequent purification, and can be glycosylated. However, in general, protein production in CHO cells is expensive and may provide variable outcomes, namely in laboratories without previous experience. While achievable yields may be influenced by the nucleotide sequence, there are other aspects of the process which offer space for optimization, like gene delivery method, cultivation process or expression plasmid design. Polyethylenimine (PEI)-mediated gene delivery is frequently employed as a low-cost alternative to liposome-based methods. In this work, we are proposing a TGE platform for universal medium-scale production of antibodies and other proteins in CHO cells, with a novel expression vector allowing fast and flexible cloning of new genes and secretion of translated proteins. The production cost has been further reduced using recyclable labware. Nine days after transfection, we routinely obtain milligrams of antibody Fabs or human lactoferrin in a 25 mL culture volume. Potential of the platform is established based on the production and crystallization of antibody Fabs and their complexes. Full article
Show Figures

Figure 1

Back to TopTop